WO1995007293A1 - Peptide inhibant la phospholipase c - Google Patents
Peptide inhibant la phospholipase c Download PDFInfo
- Publication number
- WO1995007293A1 WO1995007293A1 PCT/JP1994/001486 JP9401486W WO9507293A1 WO 1995007293 A1 WO1995007293 A1 WO 1995007293A1 JP 9401486 W JP9401486 W JP 9401486W WO 9507293 A1 WO9507293 A1 WO 9507293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arg
- leu
- tyr
- peptide
- lys
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel peptides that inhibit phospholipase C (hereinafter, referred to as PLC) activity.
- PLC for example, inositol phospholipid PLC (hereinafter referred to as PI-PLC) has been separated and purified from various tissues, and ⁇ , ⁇ ⁇ y, (5-4 the presence of type nine Aisozaimu have been revealed. 7 ⁇ as the type, and 7 and 2 of the two is known [SG Rhee et al., Science (Science), 244, 546-550 ( 1989) Y. Homma et al., Biochemical. Journal (Biochem. J.), 269, 13-18 (1990)], both of which have been shown to play important roles in growth factor signaling.
- PI-PLC inositol phospholipid PLC
- the structural features of the ⁇ - and S-types are characterized by the inclusion of the oncogenic src-related regions, the SH2 and SH3 (SH2 / SH3) regions between the I and II regions common to 3, 7, and ⁇ .
- SH2 and SH3 SH2 / SH3
- the y-type SH2 domain is essential for interaction with receptor tyrosine kinases [D.
- N-formyl-methionyl-leucylaffine-l-alanine is known to cause inflammation via granulocytes and polymorphonuclear leukocytes (PMN). It has been reported that PLC is involved in the signal transduction system of this receptor (Science, 232, 97-100 (1986)), and platelet-derived growth factor (PDGF) (Science, 248, 1009 (1990)), and PLC-72 is present as a component in the PDGF-dependent vascular smooth muscle cell proliferation signal transduction system.
- PDGF platelet-derived growth factor
- J 'and J 2 is or represents hydrogen, or J 1 and J 2 are together a connexion single Represents a bond
- W represents hydrogen, substituted or unsubstituted alkanol, substituted or unsubstituted aroyl or cumaryl
- X represents a single bond
- Y may represent a single bond or one Pr 0 -V a1 —
- Z represents hydroxy or amino.
- the substituted or unsubstituted alkanoyl has 1 to 20 carbon atoms, for example, formyl, acetyl, propionyl, butyryl, isobutylyl, norkeryl, isopalleryl, bivaloyl, caprylyl, lauroyl, miroyl Examples include restyl, palmitoyl, and stearoyl.
- the substituent include carboxy, alicyclic alkyl, and phenyl.
- Examples of the alicyclic alkyl include those having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- Examples of the substituted or unsubstituted aroyl include benzoyl and naphthoyl.
- the substituent include hydroxy having 1 to 3 substituents.
- Trt Trityl
- Table 1 shows specific examples of the compound (I). ⁇ 3 ⁇ 4 ⁇ Mouth arrangement
- Compound (I) is synthesized by a solid phase synthesis method using an automatic peptide synthesizer.
- the peptide-bound solid support obtained by the solid phase method is treated with hydrogen fluoride or TFA to release the peptide from the solid support and at the same time remove the protecting group of the amino acid side chain.
- Amidation of C-terminal amino acids can be performed using a peptide synthesizer manufactured by Applied Biosystems, Inc., Foster City, California, USA (hereinafter referred to as ABI) using P-methyl-benzhydrylamine (BHA). ) —Use resin (manufactured by ABI).
- a linkamide resin or a linkamide-MBHA (4-methylbenzhydrylamine) resin (Calbiochem-Nova Piochem Japan).
- a carboxylic acid component and a condensing reagent for example, PyBOPZHOB t / NMM] are used in the same manner as in elongation of the peptide chain. Or condensation using an activated carboxylic acid such as an acid anhydride or an acid chloride of the carboxylic acid component.
- the above reaction is carried out on a synthetic resin, and after completion of the reaction, the desired peptide derivative is cut out from the resin.
- the thus obtained crude product of the peptide is purified by high performance liquid chromatography (hereinafter referred to as HPLC) using a reversed phase column to obtain a pure product.
- HPLC high performance liquid chromatography
- the cyclic peptide having an SS bond can be obtained by oxidizing the linear peptide obtained as described above with an air solution in an aqueous solution of a weak base, or by oxidizing such as potassium ferrosyanide or oxidized glutathione. Obtained by oxidizing
- the compound (I) obtained by the present invention exhibits excellent PLC inhibitory activity, cell growth inhibitory activity and antibacterial activity.
- a solution having the composition shown in Table 2 was prepared on ice in advance, and the reaction was started by heating to 37 ° C. After incubation for 10 minutes, the reaction was stopped by adding 2 ml of a mixed solution of chloroform and methanol (2: 1, V / V). The generated inositol phosphate was extracted with 0.5 ml of IN hydrochloric acid. Centrifuged (2000 ⁇ g, 3 minutes) by the two-phase partition, measured scintillation of 3 H amount contained in the supernatant 0.7 ml.
- Table 3 shows the concentrations of the peptides and aqueous solutions used in the test.
- Table 3 shows the inhibition rates of the obtained test peptides.
- the medium was changed again with serum-free DMEM medium, and the labeling reagents 5-bromo-2, -deoxyperidine (BrdU) and 5-fluoro-2'-deoxyperidine (FdU) [10: 1] were diluted 1000-fold with the same medium. 0.5 ml was added to each well and cultured for 2 hours. Next, the medium was removed, and the cells were fixed with an acetic acid-ethanol solution. The fixed cells were stained according to the method of a cell proliferation detection kit manufactured by Amersham, and further stained with 1% Giemsa solution (Merck).
- the cell growth inhibition rate (X) was determined from the following equation, where A is the proliferation activity when no peptide is added, and B is the proliferation activity when the test peptide is added.
- Table 4 shows the inhibition rates of the obtained test peptides.
- Antibacterial activity is measured by agar dilution method using a medium (pH 7.0) consisting of 3 g / l of Pacto Tripton (manufactured by Difco), lg / 1 of meat extract, lg / 1 of dulkose, and 16 g / l of agar. did.
- a medium pH 7.0
- the minimum inhibitory concentration (MIC) of compound (I-13) and compound (I-14) was 166 g / ml.
- Examples 1 to 4 are examples of peptide synthesis using the Shimadzu Peptide Synthesizer PS SM8 and operating the synthesizer according to the company's synthesis program using Shimadzu's reagents and solvents. Show. Amino acid condensation reactions were carried out under standard conditions by the Fmoc method (Basic and Experimental Peptide Synthesis, Nobuo Izumiya et al. (Maruzen)).
- Fmoc-Cys (Trt) was synthesized on the carrier.
- step (4) a condensation reaction is performed in step (4) using Fmoc-Val-OH, and then the washing step of (5) is performed.
- Fmoc-Val-Cys (Trt) was synthesized on a carrier resin.
- steps (1) to (3) were sequentially repeated to obtain a carrier resin to which the protective peptide was bound.
- step (4) 300 / mol of Fmoc-Pro-0H, Fmoc-Tyr (t-Bu) -0H, Fmoc-Arg (Pmc) -0H, Fmoc-Leu-OH, Fmoc-Arg (Pmc )-0H, Fmoc-Met-0H, Fmoc-Lys (t-Boc) -0H, Fmoc-Arg (Pmc) -0H, Fmoc-Tyr (t-Bu) -0H, Fmoc-Leu-OH, Fmoc-Cys (Trt) -OH was used.
- the obtained carrier resin was thoroughly washed with methanol and butyl ether, and then dried under reduced pressure for 2 hours.
- 1 ml of 10% TFAZ methylene chloride was placed in the reaction vessel containing the dried carrier resin, stirred, and allowed to drop naturally from the bottom of the reaction vessel, and the liquid was recovered.
- 1 ml of 20% TFAZ methylene chloride was added, and the above operation was repeated twice.
- the solvent was distilled off from the recovered solution that was naturally reduced by an evaporator, and the peptide was cut out from the resin. Furthermore 8 2.
- a peptide having a phospholipase C inhibitory activity can be provided.
- Xaa at position 1 represents N— (n—force prill) —L—cysteine.
- Xaa at position 13 represents L-cysteinamide.
- Xaa at position 1 is N— (n—caprylyl) —L— C for cysteine.
- Xaa at position 13 represents L_cysteinamide.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69408299T DE69408299T2 (de) | 1993-09-10 | 1994-09-08 | Phospholipase c inhibitierendes peptid |
ES94926371T ES2114220T3 (es) | 1993-09-10 | 1994-09-08 | Peptido inhibidor de la fosfolipasa c. |
EP94926371A EP0672679B1 (en) | 1993-09-10 | 1994-09-08 | Phospholipase c inhibiting peptide |
US08/432,143 US5847074A (en) | 1993-09-10 | 1994-09-08 | Phospholipase C-inhibiting peptides |
CA002149038A CA2149038C (en) | 1993-09-10 | 1994-09-08 | Phospholipase c-inhibiting peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22539793 | 1993-09-10 | ||
JP5/225397 | 1993-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995007293A1 true WO1995007293A1 (fr) | 1995-03-16 |
Family
ID=16828725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001486 WO1995007293A1 (fr) | 1993-09-10 | 1994-09-08 | Peptide inhibant la phospholipase c |
Country Status (7)
Country | Link |
---|---|
US (1) | US5847074A (ja) |
EP (1) | EP0672679B1 (ja) |
AT (1) | ATE162850T1 (ja) |
CA (1) | CA2149038C (ja) |
DE (1) | DE69408299T2 (ja) |
ES (1) | ES2114220T3 (ja) |
WO (1) | WO1995007293A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028466A1 (fr) * | 1995-03-10 | 1996-09-19 | Kyowa Hakko Kogyo Co., Ltd. | Peptides inhibant la phospholipase c |
WO2002006307A1 (fr) * | 2000-07-17 | 2002-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Fk228 reduit et son utilisation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677420A (en) * | 1995-03-10 | 1997-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Phospholipase c-inhibiting peptides |
US20020107193A1 (en) * | 2000-11-09 | 2002-08-08 | Glazner Gordon W. | Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
US6527912B2 (en) | 2001-03-30 | 2003-03-04 | Lam Research Corporation | Stacked RF excitation coil for inductive plasma processor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018062A1 (en) * | 1992-03-11 | 1993-09-16 | Kyowa Hakko Kogyo Co., Ltd. | Peptide which inhibits phospholipase c |
-
1994
- 1994-09-08 WO PCT/JP1994/001486 patent/WO1995007293A1/ja active IP Right Grant
- 1994-09-08 US US08/432,143 patent/US5847074A/en not_active Expired - Fee Related
- 1994-09-08 AT AT94926371T patent/ATE162850T1/de not_active IP Right Cessation
- 1994-09-08 ES ES94926371T patent/ES2114220T3/es not_active Expired - Lifetime
- 1994-09-08 CA CA002149038A patent/CA2149038C/en not_active Expired - Fee Related
- 1994-09-08 EP EP94926371A patent/EP0672679B1/en not_active Expired - Lifetime
- 1994-09-08 DE DE69408299T patent/DE69408299T2/de not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018062A1 (en) * | 1992-03-11 | 1993-09-16 | Kyowa Hakko Kogyo Co., Ltd. | Peptide which inhibits phospholipase c |
Non-Patent Citations (1)
Title |
---|
J. Biol. Chem., Vol. 267, No. 30 (1992), YOSHIMI HOMMA et al., "Inhibitory Effect of src Homology (SH) 2/SH3 Fragments of Phospholipase C-r on the Catalytic Activity of Phospholipase C Isoforms", pp. 21844-21849. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028466A1 (fr) * | 1995-03-10 | 1996-09-19 | Kyowa Hakko Kogyo Co., Ltd. | Peptides inhibant la phospholipase c |
WO2002006307A1 (fr) * | 2000-07-17 | 2002-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Fk228 reduit et son utilisation |
US7056884B2 (en) | 2000-07-17 | 2006-06-06 | Astellas Pharma Inc. | Reduced FK228 and use thereof |
Also Published As
Publication number | Publication date |
---|---|
DE69408299T2 (de) | 1998-08-20 |
ATE162850T1 (de) | 1998-02-15 |
EP0672679B1 (en) | 1998-01-28 |
DE69408299D1 (de) | 1998-03-05 |
CA2149038A1 (en) | 1995-03-16 |
US5847074A (en) | 1998-12-08 |
EP0672679A1 (en) | 1995-09-20 |
EP0672679A4 (en) | 1995-12-06 |
ES2114220T3 (es) | 1998-05-16 |
CA2149038C (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Glass et al. | Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein | |
Rawal et al. | Structural specificity of substrate for S-adenosylmethionine protein arginine N-methyltransferases | |
Choi-Miura et al. | Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J) | |
JPH07165797A (ja) | 立体配座的に安定化された細胞接着ペプチド | |
Váradi et al. | Synthesis of PAF, an antifungal protein from P. chrysogenum, by native chemical ligation: native disulfide pattern and fold obtained upon oxidative refolding | |
EP1116727B1 (en) | Peptide derivative | |
AU697378B2 (en) | Antibiotic cryptdin peptides and methods of their use | |
WO1995007293A1 (fr) | Peptide inhibant la phospholipase c | |
Rudnick et al. | Use of photoactivatable peptide substrates of Saccharomyces cerevisiae myristoyl-CoA: protein N-myristoyltransferase (Nmt1p) to characterize a myristoyl-CoA-Nmt1p-peptide ternary complex and to provide evidence for an ordered reaction mechanism. | |
JP2584783B2 (ja) | 新規抑制因子ペプチド | |
US6197535B1 (en) | Methods for purifying and assaying a conus γ-carboxylase | |
EP0584374B1 (en) | Peptide which inhibits phospholipase c | |
Hendrix et al. | Synthesis of a protected peptide corresponding to residues 1-25 of the. beta.-amyloid protein of Alzheimer's disease | |
Ponstingl et al. | Mapping of ligand binding sites, epitopes, and posttranslational modifications on protein sequences—Tubulin as an example | |
US5677420A (en) | Phospholipase c-inhibiting peptides | |
WO1996028466A1 (fr) | Peptides inhibant la phospholipase c | |
WO2023048262A1 (ja) | 酵素を用いたペプチドライゲーション | |
PL213309B1 (pl) | Sposób hydrolizy wiazania peptydowego | |
JPH09173087A (ja) | Atpおよび核酸に結合し、ヘリカーゼおよびatpアーゼの性質を有すると推定される蛋白質 | |
JP2584839B2 (ja) | インヒビターペプチド▲i▼および▲ii▼ | |
JP2733023B2 (ja) | スカベンジャー受容体のリガンド取り込みを阻害するペプチド化合物 | |
JP2001253899A (ja) | ペプチドライブラリーの製造方法 | |
Odani et al. | On the molecular origin of charge heterogeneity of rat liver fatty acid-binding protein (Z-protein) | |
JP5245053B2 (ja) | トリペプチド合成方法、トリペプチド合成酵素溶液、およびその製造方法 | |
David | Primary Structural Determinants Essential for Potent Inhibition of CAMP-dependent Protein Kinase by Inhibitory Peptides Corresponding to the Active Portion of the Heat-stable Inhibitor Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08432143 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2149038 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994926371 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994926371 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994926371 Country of ref document: EP |